# A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

> **NCT03693014** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 69 (actual)

## Conditions studied

- Metastatic Cancer
- Melanoma Cancer
- Lung Cancer
- Bladder Cancer
- Renal Cancer
- Head/Neck Cancers

## Interventions

- **RADIATION:** Stereotactic Body Radiotherapy
- **BIOLOGICAL:** Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab

## Key facts

- **NCT ID:** NCT03693014
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-01
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693014, "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03693014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*